Tiantan Biological Pushes Chromatography and Recombinant Technology to Widen China's Blood Product Access
Start here
China National Biotec Group's Tiantan Biological is industrializing blood products through multi-step chromatographic purification and recombinant DNA technology. Its immunoglobulin and recombinant human coagulation factor VIII products are already approved. In September 2023, China approved its first fourth-generation 10% intravenous immunoglobulin made by full chromatography, with purity above 98%; a 2.5 g small-size presentation followed in 2025. In June 2026, the country's first 20% subcutaneous immunoglobulin gained approval, enabling patients to treat at home after professional training. The program aims to improve patient access to plasma-derived and recombinant therapies.
Written by a model from the reports · updated 4 hours ago
Coverage timeline
Follow the coverage to see the different angles.
- mp.weixin.qq.comCNBG Tiantan Expands Blood Products via Chromatography and Recombinant Technology to Improve Access
China National Biotec Group's Tiantan Biological is advancing industrialization of blood products through multi-step chromatographic purification and recombinant DNA technology; its immunoglobulin and recombinant human coagulation factor VIII products are approved. In September 2023, China's first fourth-generation 10% intravenous immunoglobulin made by full chromatography was approved, with purity above 98%, and a 2.5 g small-size presentation was added in 2025. In June 2026, China's first 20% subcutaneous immunoglobulin was approved, allowing home treatment after professional training.
Heat trend for this story
Heat now 8·Peak in the comparable set 10 (Oct 23 19:00)·Change over 24h in the comparable set –·Participants now 1
Participants counted above, heat below. The trend compares only the participants observed in full throughout, so its set can be smaller than the heat figure itself. Move the pointer or click the chart for an hour's reading; the left and right arrow keys work too.